NN2211-4077 Retrospective collection of effectiveness and safety data from patients treated with liraglutide or DPP-4 inhibitor in primary care in Europe

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/24533
• EU PAS number:
  EUPAS8135
• Study ID:
  24533
• Official title and acronym:
  NN2211-4077 Retrospective collection of effectiveness and safety data from patients treated with liraglutide or DPP-4 inhibitor in primary care in Europe
• DARWIN EU® study:
  No
• Study countries:
  France

  Germany

  Spain

  United Kingdom
• Study description:
  This study is conducted in Europe.The aim of this study is to demonstrate the clinical effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in routine primary care in Europe.
• Study status:
  Finalised

Research institutions and networks

Institutions

Novo Nordisk

Not applicable

Study timelines

Date when funding contract was signed

Actual: 18/01/2012

Study start date

Actual: 06/08/2013

Date of final study report

Actual: 09/03/2015

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Novo Nordisk A/S

Study protocol

Initial protocol

4077-protocol-version-2-7-nw-redacted

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable